Immune-G is a ratio-controlled botanical composition addressing four root causes of immunosenescence through five validated mechanisms, with USPTO provisional patent protection filed June 2026.
Progressive loss of immune competence after age 55 drives multi-morbidity, infectious susceptibility, and accelerated biological aging — affecting more than 1.5 billion people globally.
No approved pharmaceutical or nutraceutical agent simultaneously addresses all four root-cause mechanisms: PHD hyperactivation, myeloid skewing, inflammaging, and ferroptotic HSC attrition.
NMN, resveratrol, and NAD+ products lead the category but lack patent protection, mechanistic precision, or validated clinical rationale.
The healthspan economy is enormous and still searching for its defining, defensible product.
The inventive core is a non-obvious selective redox modulation mechanism that preserves PHD inhibition and HIF-1α stabilization — a distinction not present in any prior art botanical combination.
Drives HSC quiescence and self-renewal preservation.
ROS modulation without PHD co-factor antagonism — HIF-1α stays preserved.
Suppresses SASP, IL-6, and TNF-α — reversing inflammaging.
HSC lineage reset with senolytic activity restores naive T-cell populations.
LIP chelation protects the age-related HSC pool from oxidative attrition.
USPTO Provisional filed — 41 claims (4 independent, with Markush structural analogues covering primary active compound classes, structural analogues, prodrugs, and pharmacologically active metabolites). Claims 20–21 protect the selective redox modulation mechanism as a non-obvious inventive step.
1,000+ subjects studied in cyclophosphamide myelosuppression models. A 4-group mechanistic study and Colby synergy validation are planned, alongside a D-galactose aging model validation in Phase 1.
DSHEA supplement launch targeted within 6 months for the aging indication, running in parallel with the FDA Botanical Drug Guidance (2016) dual-track pathway toward IND. Free of cyanogenic glycosides; ICH Q1A(R2) 12-month stability claimed.
Serial entrepreneur with 15 years in banking and venture-building. Concurrently CEO of Immune-G Ltd. and DetentionPro.
Healthcare specialist leading preclinical research and formulation development.
Focused on botanical pharmacology and hematopoietic research underlying the platform's mechanism work.
Patent filed. Dual-track regulatory path open. We're sharing materials with investors who think about aging biology and execution-stage de-risking the same way we do.